DXCM Dexcom Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
22:35
Aug 05
Aug 05
Watch Abbott, DexCom on CGM read-through
Watch ABT and DXCM as the clearest medical-device beneficiaries of TTM's CGM component strength; research read-through only, no author-owned long.
MED
13:06
Aug 04
Aug 04
A news wire reports a broad list of price target increases from multiple analysts across dozens.
A news wire reports a broad list of price target increases from multiple analysts across dozens of stocks, with no directional commentary from the account itself.
11:40
Jul 31
Jul 31
A news wire reports a broad wave of price target increases across multiple stocks from various.
A news wire reports a broad wave of price target increases across multiple stocks from various analysts, with no explicit directional calls made by the account itself.
20:30
Jul 30
Jul 30
Management raised the full-year revenue and margin guidance, signaling confidence in sustained demand, strong product performance, and improving operational efficiencies, partially offset by FX headwinds.
HIGH
20:06
Jul 30
Jul 30
Dexcom reported second quarter 2026 earnings with revenue up 13 percent year-over-year and GAAP.
Dexcom reported second quarter 2026 earnings with revenue up 13 percent year-over-year and GAAP net income of 249.1 million dollars.
13:00
Jul 16
Jul 16
U.S. Type-2 CGM reimbursement could land in the fall, unlocking roughly 10 million Medicare beneficiaries and a multi-billion dollar opportunity; Abbott is pre-positioning sales force and distribution. — A CGM reimbursement expansion at CMS would enlarge the addressable market for both Abbott and Dexcom, with meaningful timing-driven sales upside.
MED
21:56
May 21
May 21
Long medtech and digital health names as rising semiconductor content in medical devices drives.
Long medtech and digital health names as rising semiconductor content in medical devices drives growth in imaging, monitoring, robotics, and wearables.
HIGH
12:24
May 15
May 15
Activist investor Elliott Investment Management took a stake in Dexcom (DXCM) and reached.
Activist investor Elliott Investment Management took a stake in Dexcom (DXCM) and reached a settlement.
HIGH
20:22
May 14
May 14
Activist investor Elliott Management disclosed a long stake in Dexcom (DXCM) and will place two.
Activist investor Elliott Management disclosed a long stake in Dexcom (DXCM) and will place two independent directors on the board.
HIGH
12:00
May 06
May 06
Dexcom's next-gen sensor is a key part of Insulet's integration roadmap, reinforcing their partnership.
HIGH
20:15
May 04
May 04
The tweet is a brief reply mentioning Dexcom stock without any directional opinion, forecast.
The tweet is a brief reply mentioning Dexcom stock without any directional opinion, forecast, or market context.
HIGH
00:43
May 01
May 01
Bearish view on DXCM as maturing CGM market, single-product risk.
Bearish view on DXCM as maturing CGM market, single-product risk, and GLP-1 headwinds drive multiple compression similar to RMD.
HIGH
00:27
May 01
May 01
Avoid or short DXCM because its core business is decelerating in a maturing market.
Avoid or short DXCM because its core business is decelerating in a maturing market, making the T2 NIT CMS approval insufficient to justify ownership.
HIGH
00:26
May 01
May 01
The author criticizes owning Dexcom for a T2 NIT CMS approval while core growth slows.
The author criticizes owning Dexcom for a T2 NIT CMS approval while core growth slows, signaling a maturing market and downside risk.
HIGH
00:26
May 01
May 01
The author warns that owning Dexcom for a T2 NIT CMS approval is misguided because the core.
The author warns that owning Dexcom for a T2 NIT CMS approval is misguided because the core business is slowing in a maturing market, signaling a bearish outlook.
HIGH
00:19
May 01
May 01
Bearish view on medtech stocks/ETF as the speaker expects further multiples compression.
Bearish view on medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.
HIGH
20:30
Apr 30
Apr 30
Management reaffirmed revenue guidance with a record global new patient quarter and raised operating margin and EBITDA margin guidance, signaling confidence in continued strong growth and operational leverage despite geopolitical uncertainties.
HIGH
11:43
Apr 22
Apr 22
Bearish view on DXCM, RMD, and ISRG because accelerating declines in bariatric procedures.
Bearish view on DXCM, RMD, and ISRG because accelerating declines in bariatric procedures for ISRG signal that GLP-1 drugs are reducing demand for related medical devices and services, extending to diabetes management and respiratory care.
HIGH
11:42
Apr 22
Apr 22
Bearish view on DXCM and RMD because accelerating declines in bariatric procedures due to GLP-1.
Bearish view on DXCM and RMD because accelerating declines in bariatric procedures due to GLP-1 drug adoption signal a structural headwind for companies exposed to obesity and diabetes-related treatment demand.
HIGH
13:00
Feb 18
Feb 18
Omnipod 5 is already compatible with Dexcom's new 15-day G7 sensor from day one, reducing risk of integration delays and preserving momentum. — This pre-emptive integration ensures no supply chain or compatibility issues that could slow Omnipod growth or sensor adoption.
HIGH
22:00
Feb 09
Feb 09
Dexcom has selected ON's low-power analog front end for its CGMs, indicating a direct supply relationship and design win in a high-value medical application.
HIGH
About DXCM Analyst Coverage
Buzzberg tracks DXCM (Dexcom) across 8 sources. 0 bullish vs 0 bearish calls from 13 analysts. Sentiment: evenly split. 22 total trade ideas tracked. Latest voices: TheValueist, DeItaone, Jereme Sylvain.